Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Early Detection of Alzheimer’s Protein Biomarker with Home Blood Test with Dr. Rany Aburashed Neurogen Biomarking TRANSCRIPT
Download PDFApr 30, 2025
Dr. Rany Aburashed, CEO and Founder of Neurogen Biomarking, is using a blood-based biomarker looking at p-tau 217 to detect early signs of Alzheimer's disease, up to 8-10 years before the onset of clinical symptoms. The company has built an ecosystem to provide patients with a comprehensive health assessment with an at-home blood test, cognitive testing, access to neurologists, and education on lifestyle changes that can support a good quality of life. Their mission is to take a proactive rather than the current reactive approach to diagnosing and slowing the progression of cognitive decline.
Rany explains, "The challenge for us, and this is what I saw from years of clinical practice and hospital management, is that a disease like Alzheimer's operates almost like a green light. Life is okay, you're having minor issues, but for the most part, you're moving along. Then suddenly you notice a sentinel event, which then becomes that red light, and now you have Alzheimer's dementia. And so the issue that is at the core of Alzheimer's is early detection. Is there a way for us to detect things earlier and, in turn, provide patients with an opportunity to take control of their dementia and make the necessary changes in treatments?"
"In the current setting, the way that we do it in the United States and around the world is really reactive and it is too late by the time your mother or father is developing cognitive complaints. It's very easy to ignore the early stages of it because you can function for three to five years without really anything dramatic happening. So suddenly, when that dramatic instance occurs, for example, you leave the stove on, or you get lost driving back to your house, something that's very obviously outside of the normal, that might trigger you to say, "Let's get Mom checked."
"At launch, our focus is on using the biomarker called p-tau 217. This biomarker can be detected now with more technologies in the blood at microscopic levels, and we couldn't do that effectively 10 or 15 years ago. That science has caught up, and the technology has caught up to a point that now, even 8 to 10 years before any significant clinical symptoms occur, we're able to detect if this protein is elevated. Now, if this protein is elevated, depending on the assay that we use, it's about 93%-97% sensitive for potentially developing Alzheimer's long-term. So it's a good protein to use as a triage protein."
#NeurogenBiomarkings #Biomarkers #BloodBiomarkers #Alzheimers #AlzheimersDisease #CognitiveDecline #Dementia #EarlyDetection #Neurologists
